Back to Search
Start Over
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
- Source :
- Biomarker Research, Vol 10, Iss 1, Pp 1-12 (2022)
- Publication Year :
- 2022
- Publisher :
- BMC, 2022.
-
Abstract
- Abstract Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and although these indicators have a certain predictive effect, their predictive performance is not good. Therefore, clinicians must make adjustments to recognize markers. This is a review article that summarized immunotherapeutic biomarkers according to the “seed-soil-environment”, generalizes primary resistance to immunotherapy, and summarizes the integration of markers.
Details
- Language :
- English
- ISSN :
- 20507771
- Volume :
- 10
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Biomarker Research
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.86f0fe2925234c638aaa40202e0c2967
- Document Type :
- article
- Full Text :
- https://doi.org/10.1186/s40364-022-00355-7